Venture capitalist Gary Shields has been added to the Advisory Board of medical non-profit, The CureScience Institute. Mr. Shields brings expertise to help guide CureScience’s focus on providing therapies based on data- and patient-centric approaches, as well as a new need for COVID-19 treatments.
"Data-centricity and patient-centricity are the core tenants of our mission and vision. Our three-pronged approach of bringing innovations, patient engagement, and care management is essential to realize the goals of precision medicine," said CureScience Interim CEO Dr. Shashaanka Ashili. "Gary brings decades of venture capital experience, and his insights would be instrumental in fostering relationships with innovators."
Mr. Shields is the founder of venture capital company Avtech Ventures, and co-founder of investment bank Flemming Lessard & Shields. An experienced investment banker, he brings more than 30 years of experience in capitalization, investment and transactions.
"The Institute's unique value of empowering the patients by making them the stakeholders within the ecosystem is very promising and exciting," said Mr. Shields. "Working with startups and building a translational ecosystem is critical to achieving the goals of precision medicine."